Antisense therapy for cancer

IDrugs

Volumn 1, Issue 2, 1998, Pages 199-205

  Orr, Rosanne M ^a   Monia, Brett P ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0006081344     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Milligan JF, Matteucci MD, Martin JC: Current concepts in antisense drug design. J Med Chem (1993) 36:1923-1937.
2. Crooke ST: Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol (1993) 32:329-376.
3. Tidd DM: Specificity of antisense oligonucleotides. Perspect Drug Discov Design (1996) 4:51-60.
4. Bennett CF, Chiang H, Shoemaker JE, Mirabelli CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol (1992) 41:1023-1030.
5. Marcussen E, Brugger J, Bennett C, Dean N: Cellular uptake and activity of phosphorothioate oligonucleotides targeting PKC-α. Proc Am Assoc Cancer Res (1997) 38:316.
6. Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L: Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood (1996) 88:731-741.
7. Spiller DG, Tidd DM: Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabili-sation of human leukaemia cells with streptolysin O. Antisense Res Dev (1995) 5:13-21.
8. Fisher TL, Terhorst T, Cao X, Wagner RW: Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res (1993) 21:3857-3865.
9. Iversen P: In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetics prologue. Anticancer Drug Des (1991) 6:531-538.
10. Geary RS, Leeds JM, Heniy SP, Monteith DK, Levin AA: Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxy-nucleotides. Anticancer Drug Des (1997) 12:383-393.
11. Rifal A, Brysch W, Fadden K, Clark J, Schlingensiepen K-H: Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am J Path (1996) 149:717-725.
12. Henry SP, Monteith D, Levin AA: Antisense oligonucleotide inhibitors for the treatment of cancer: 2 Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des (1997) 12:395-408.
13. Galbraith WM, Hobson WC, Giclas PC, Scheeler PJ, Agrawal S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev (1994) 4:201-206.
14. Gewirtz AM, Calabretta B: A c-myb antisense oligodeoxynucleotide inhibits normal human hematopolesis in vitro. Science (1988) 242:1303-1306.
15. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxy-nucleotides: An in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA (1991) 88:2351-2355.
16. Paine RM, Weston BJ, Clink HMcD, Kohn J, Neville AM, McGhee KG, Harrap KH: Toxicity and immunosuppresslve activity of binary combinations of 2'-deoxycoformycin and 2'-deoxya-denosine. Cancer Treat Rep (1981) 65:259-266.
17. Ratajczak MZ, Kant JA, Luger SM, Hiyiya N, Zhang J, Zon G, Gewirtz AM: In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA (1992) 89:11823-11827.
18. Gewirtz AM: Developing oligonucleotide therapeutics for human leukemia. Anticancer Drug Des (1997) 12:341-358.
19. Reed J, Tsujimoto Y, Epstein S, Cuddy M, Slabiak T, Nowell P, Croce C: Regulation of bcl-2 gene expression in lymphoid cell lines containing t(14;18) or normal #18 chromosomes. Oncogene Res (1989) 4:271-282.
20. Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S, Cohen J: Antisense-mediated inhibition of bcl-2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res (1990) 50: 6565-6570.
21. Cotter FE, Johnson P, Hall P, Pocock C, Al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene (1994) 9:3049-3055.
22. Cotter FE, Corbo M, Raynaud F, Orr R, Pocock C, Bryan B, Harper M, Webb A, Clarke P, Judson I, Cunningham D: Bcl-2 antisense therapy in lymphoma:- In vitro and in vivo mechanisms, efficacy, pharmacokinetic and toxicity studies. Ann Oncol (1996) 7:3.
23. Raynaud FI, Orr RM, Goddard PG, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide anti-sense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther (1997) 281:420-427.
24. Webb A, Cunningham D, Cotter F, Clarke PA, di Stephano F, Ross P, Corbo M, Dziewanowska Z: bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349:1137-1141.
25. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (1992) 258:607-614.
26. Dean NM, McKay R, Condon TP, Bennett CF: Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem (1994) 269:16416-16424.
27. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D: Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res (1996) 56:3499-3507.
28. Nemunaitis J, Eckhardt G, Dorr A, Pribble J, Smith R, Smith J, Bruce N, Ognoskie D, Von Hoff D: Phase I evaluation of CGP 64128A, an antisense inhibitor of protein kinase C-α (PKC-α), in patients with refractory cancer. Proc Am Soc Clin Oncol (1997) 16:246a.
29. Sikic BI, Yuen J, Halsey GA, Fisher JP, Pribble JP, Smith RM, Dorr A: A phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS 3521) delivered by 21-day continuous intravenous infusion. Proc Am Soc Clin Oncol (1997) 16:212a.
30. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidid H, Mischak H, Finkenzeller G, Marme D, Rapp UR: Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature (1993) 364:249-252.
31. Carroll MP, May WS: Protein kinase C-mediated serine phosphorylation directly activates raf-1 in murine hematopoletic cells. J Biol Chem (1994) 269:1249-1256.
32. McCormick F: Ras GTPase activating protein: signal transmitter and signal terminator. Cell (1989) 56:5-8.
33. Hall A: The cellular functions of small GTP-binding proteins. Science (1990) 249:635-649.
34. McCormick F: Ras Oncogenes. In: Oncogenes and the Molecular Origins of Cancer. Weinberg RA (Ed), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) 124-145.
35. Rapp UR: Role of raf oncogenes in lung carcinogenesis. Proc. Intl. Conf. Hormones, Growth Factors and Oncogenes in Pulmonary Carcinoma. Dunbar BS (Ed), Plenum, London (1987) 122-137.
36. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Anti-tumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med (1996) 2:668-672.
37. Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann K-H, Moser H, Fabbro D: Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA (1996) 93:15481-15484.
38. Geiger T, Muller M, Monia BP, Fabbro D: Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res (1997) 3:1179-1185.
39. Der CJ, Krontiris TG, Cooper GM: Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA (1982) 79:3637-3640.
40. Goldfarb M, Shimizu K, Perucho M, Wigler M: Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature (1982) 296:404-409.
41. Parada LF, Tabin CJ, Shih C, Weinberg RA: Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 297:474-478.
42. Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M: T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature (1982) 298:343-347.
43. Chen G, Oh S, Monia BP, Stacey D: Antisense oligonucleotides demonstrate a dominant role of C-kl-ras proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem (1996) 271:28259-28265.
44. Bennett CF, Dean N, Ecker DJ, Monia BP: Pharmacological activity of phosphorothioate antisense oligonucleotides: In vivo studies. In: Methods in Molecular Medicine: Antisense Therapeutics. Agrawal S (Ed), Humana Press, Totowa, NJ (1995) 13-46.
45. Cowsert LM: In vitro and in vivo activity of antisense inhibitors of res: potential for clinical development Anti-Cancer Drug Des (1997) 12:359-371.
46. Geiger T, Muller M, Dean NM, Fabbro D: Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des (1998) 13:35-45